Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;124(6):368-74.
doi: 10.1111/j.1600-0404.2011.01489.x. Epub 2011 Feb 8.

The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression

O S Cohen  1 , I Prohovnik, A D Korczyn, L Ephraty, Z Nitsan, R Tsabari, S Appel, H Rosenmann, E Kahana, J Chapman
Affiliations

The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression

O S Cohen et al. Acta Neurol Scand. 2011 Dec.

Abstract

Objectives: To develop a scale sensitive for the neurological manifestations of Creutzfeldt-Jakob disease (CJD).

Methods: A 26-item CJD neurological status scale (CJD-NS) was created based on characteristic disease manifestations. Each sign was assigned to one of eight neurological systems to calculate a total scale score (TSS) and a system involvement score (SIS). The scale was administered to 37 CJD patients, 101 healthy first-degree relatives of the patients and 14 elderly patients with Parkinson's disease (PD).

Results: The mean TSS (±SD) was significantly higher in patients with CJD (13.19 ± 5.63) compared with normal controls (0.41 ± 0.78) and PD patients (9.71 ± 3.05). The mean SIS was also significantly different between the CJD (5.19 ± 1.22) and PD (2.78 ± 1.18 P ≤ 0.01) groups reflecting the disseminated nature of neurological involvement in CJD. Using a cutoff of TSS > 4 yielded a sensitivity of 97% for CJD, and specificity of 100% against healthy controls. All individual items showed excellent specificity against healthy subjects, but sensitivity was highly variable. Repeat assessments of CJD patients over 3-9 months revealed a time-dependent increase in both the TSS and the SIS reflecting the scale's ability to track disease progression.

Conclusions: The CJD-NS scale is sensitive to neurological signs and their progression in CJD patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CJD-NS: The Creutzfeldt-Jakob disease Neurological scale.
Figure 2
Figure 2. Progression of CNS-NS Total Severity Score (TSS) relative to elapsed time between evaluations
Progression of CNS-NS Total Severity Score (TSS) relative to time. Time is presented in months and TSS was calculated as described in the methods. (2A): TSS is presented for 14 patients with at least 2 examinations. Each point represents the change between first and last examination in each patient. (2B): The change in TSS relative to disease duration for 7 patients with 3 consecutive examinations and 7 additional patients with 2 consecutive examinations.
Figure 2
Figure 2. Progression of CNS-NS Total Severity Score (TSS) relative to elapsed time between evaluations
Progression of CNS-NS Total Severity Score (TSS) relative to time. Time is presented in months and TSS was calculated as described in the methods. (2A): TSS is presented for 14 patients with at least 2 examinations. Each point represents the change between first and last examination in each patient. (2B): The change in TSS relative to disease duration for 7 patients with 3 consecutive examinations and 7 additional patients with 2 consecutive examinations.
Figure 3
Figure 3. Progression of CJD-NS System Involvement Scores
Progression of CJD-NS System Involvement Scores (SIS) relative to disease duration in seven patients who had three or more evaluations. Each line represents the scores in one patient.
See this image and copyright information in PMC

References

    1. Jakob A. Uber eigenaritge erkrankungen des zentral-nervensystems mit bemerkenswertem anatomischen befunde (spastische pseudosklerose-encephalomyelopathie mit disseminierten degenerationsherden) Z Gesamte Neurol Psychiatre. 1921;64:147–228.
    1. Brown P, Kenney K, Little B, et al. Intracerebral distribution of infectious amyloid protein in spongiform encephalopathy. Ann Neurol. 1995;38:245–53. - PubMed
    1. MacDonald ST, Sutherland K, Ironside JW. Prion protein genotype and pathological phenotype studies in sporadic Creutzfeldt–Jakob disease. Neuropathol Appl Neurobiol. 1996;22:285–92. - PubMed
    1. Goldfarb LG, Korczyn AD, Brown P, et al. Mutation in codon 200 of scrapie amyloid precursor gene linked to Creutzfeldt-Jakob disease in Sephardic Jews of Libyan and non-Libyan origin. Lancet. 1990;336:637–38. - PubMed
    1. Kretzschmar HA, Ironside JW, DeArmond SJ, et al. Diagnostic criteria for Creutzfeldt-Jakob disease. Arch Neurol. 1996;53:913–20. - PubMed

Publication types